- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00728299
The Effects of Consumption of Pomegranate Juice on Carotid Intima-Media Thickness
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Previous studies in atherosclerotic mice have shown that pomegranate supplementation reduced their macrophage oxidative stress and attenuated the development of their atherosclerosis. Further research in hypertensive humans demonstrated that pomegranate juice had an angiotensin converting enzyme (ACE)-inhibitory effect and significantly decreased systolic blood pressure.
This study will use a randomized, double-blind, placebo-controlled design with eight clinic visits (one screening visit [week -4 to -1], one baseline visit [week 0], and six treatment visits [weeks 13, 26, 38, 52, 65, and 78]).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males between the ages of 45 and 74 and females between the ages of 55 and 74 years.
Subject has ≥ 1 of the following risk factors at Visit 1 (week -4 to -1):
- current cigarette smoking (defined as any cigarette smoking within the past month)
- hypertension (blood pressure ≥ 140/90 mm Hg or using an antihypertensive medication)
- low HDL cholesterol (< 40 mg/dL)
- high LDL cholesterol (≥ 130 mg/dL and < 190 mg/dL), on statin therapy or not
- Posterior wall common carotid IMT > 0.7 mm and < 2.0 mm at Visit 2 (week 0) with an adequate image on at least one side.
- Subject understands the study procedures and signs an informed consent form.
- Normally active and judged to be in good health on the basis of medical history, physical examination, and routine laboratory tests.
Exclusion Criteria:
- Use of any pharmacologic lipid-altering medications, besides statins (e.g., fibrate derivatives, bile acid binding resins, and niacin or its analogues at doses > 400 mg/d) six weeks prior to Visit 1
- Body mass index > 40 kg/m2.
- Unstable use (< 2 months prior to Visit 1) of any supplement known to alter lipid metabolism, including but not limited to: dietary fiber supplements (including > 2 teaspoons Metamucil® or psyllium-containing supplement per day), omega-3 fatty acid supplements, sterol/stanol products, red rice yeast supplements, garlic supplements, soy isoflavone supplements or others at the discretion of the Investigator).
- History of pomegranate consumption (either eating pomegranates or drinking pomegranate juice) within the past 6 months.
Clinical evidence or history of coronary heart disease (CHD) or CHD equivalents including:
- diabetes mellitus,
- angina,
- myocardial infarction,
- transient ischemic attack,
- symptomatic carotid artery disease,
- cerebrovascular accident,
- coronary artery bypass grafting,
- percutaneous transluminal coronary angioplasty,
- peripheral arterial disease,
- abdominal aortic aneurysm,
- ankle brachial index < 0.90,
- and/or a Framingham Risk Score ≥ 16 points for men and ≥ 23 points for women (10-year CHD risk > 20%)
- Active cancer, other than non-melanoma skin cancer, within the previous two years.
- Prior diagnosis of human immunodeficiency virus (HIV) or hepatitis B or hepatitis C.
- Uncontrolled hypertension (average systolic blood pressure ≥ 160 mm Hg and/or average diastolic blood pressure ≥ 100 mm Hg).
- Untreated or unstable hypothyroidism (receiving stable dose therapy for < 4.0 months).
- Concomitant use of beta-adrenergic blockers or immunosuppressants
- Concomitant use of estrogen or progestin therapy.
- Allergy to pomegranates or pomegranate juice.
- Known allergy to blood products.
- Non-English speaking.
- Active liver disease or hepatic dysfunction as defined by elevations of ≥ 2.0 x ULN at Visit 1 in any of the following liver function tests: ALT, AST or bilirubin.
- Serum creatinine > 2.0 mg/dL recorded during screening period.
- Recent history of (within past 12 months) or strong potential for alcohol or substance abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz beer, 4 oz wine, or 1 ½ oz distilled spirits).
- Participation in another clinical study within 30 days prior to screening visit 1 (week -4 to -1).
- Has a condition the Investigator believes would interfere with evaluation of the subject, or may put subject at undue risk.
- Posterior wall common carotid IMT ≥ 2.0 mm on either side at Visit 2 (week 0).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
8 oz per day each day for 78 weeks
|
Placebo Comparator: 2
|
8 oz per day for 78 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in posterior wall common carotid intima-media thickness (IMT) progression rate in mm/yr between PomWonderful juice and placebo, utilizing non-contrast images
Time Frame: 78-90 weeks
|
78-90 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference between placebo and PomWonderful juice in internal carotid artery IMT progression rate in mm/yr
Time Frame: 78-90 weeks
|
78-90 weeks
|
Difference between placebo and PomWonderful juice in the carotid bifurcation IMT progression rate in mm/yr
Time Frame: 78-90 weeks
|
78-90 weeks
|
Difference between placebo and PomWonderful juice in the anterior wall common carotid IMT progression rate in mm/yr, without contrast agent
Time Frame: 78-90 weeks
|
78-90 weeks
|
Difference between placebo and PomWonderful juice in the anterior wall common carotid IMT progression rate in mm/yr, with contrast agent
Time Frame: 78-90 weeks
|
78-90 weeks
|
Difference between placebo and PomWonderful juice in the posterior wall common carotid IMT progression rate in mm/yr, with contrast agent
Time Frame: 78-90 weeks
|
78-90 weeks
|
Difference between placebo and PomWonderful juice in the composite IMT measure, which combines the measurements of the common and internal carotid and the carotid bifurcation in mm/yr
Time Frame: 78-90 weeks
|
78-90 weeks
|
Change from baseline to 13 weeks in hs-CRP concentration
Time Frame: 13 weeks
|
13 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael H Davidson, MD, FACC
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Radiant Development #202528
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on PomWonderful Juice
-
Roll International CorporationUnknownProstate CancerUnited States
-
San Diego State UniversityRecruiting
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedFeeding Behavior | Inhibition (Psychology)
-
Universidad Francisco de VitoriaUniversity of Alcala; University of SevilleCompleted
-
University of Colorado, DenverCompletedProstate CancerUnited States
-
Karolinska InstitutetRecruiting
-
Northumbria UniversityCompletedCognitive Impairment | Cerebrovascular CirculationUnited Kingdom
-
Bangor UniversityCompleted
-
University of ManchesterCompleted